Petrology and chemistry of ODP Site 134-828 magmatic rocks

Petrography, major and trace elements, mineral chemistry, and Sr, Nd, and Pb isotopic ratios are reported for igneous rocks drilled on the northern flank of the North d'Entrecasteaux Ridge (NDR) during Ocean Drilling Program (ODP) Leg 134 Site 828. These rocks comprise a breccia unit beneath a middle Eocene foraminiferal ooze. Both geophysical characteristics and the variety of volcanic rocks found at the bottom of Holes 828A and 828B indicate that a very immature breccia or scree deposit was sampled. Basalts are moderately to highly altered, but primary textures are well preserved. Two groups with different magmatic affinities, unrelated to the stratigraphic height, have been distinguished. One group consists of aphyric to sparsely plagioclase + clinopyroxene-phyric basalts, characterized by high TiO2 (~2 wt%) and low Al2O3 (less than 15 wt%) contents, with flat MORB-normalized incompatible element patterns and LREE-depleted chondrite-normalized REE patterns. This group resembles N-MORB. The other group comprises moderately to highly olivine + plagioclase-phyric basalts with low TiO2 (<1 wt%) and high Al2O3 (usually >15 wt%) contents, and marked HFSE depletion and LFSE enrichment. Some lavas in this group are picritic, with relatively high modal olivine abundances, and MgO contents up to 15 wt%. Both the basalts and picritic basalts of this group reflect an influence by subduction-related processes, and have compositions transitional between MORB and IAT. Lavas with similar geochemical features have been reported from small back-arc basins such as the Mariana Trough, Lau Basin, Sulu Sea, and the North Fiji Basin and are referred to as back-arc basin basalts. However, regional tectonic considerations suggest that the spreading that produced these backarc basin basalts may have occurred in the forearc region of the southwest-facing island arc that existed in this region in the Eocene.

Intermittent Fugu parathyroid hormone 1 (1–34) is an anabolic bone agent in young male rats and osteopenic ovariectomized rats

Human parathyroid hormone (hPTH) is currently the only treatment for osteoporosis that forms new bone. Previously we described a fish equivalent, Fugu parathyroid hormone 1 (fPth1) which has hPTH-like biological activity in vitro despite fPth1(1–34) sharing only 53% identity with hPTH(1–34). Here we demonstrate the in vivo actions of fPth1(1–34) on bone. In study 1, young male rats were injected intermittently for 30 days with fPth1 [30 μg–1000 μg/kg body weight (b.w.), (30fPth1–1000fPth1)] or hPTH [30 μg–100 μg/kg b.w. (30hPTH–100hPTH)]. In proximal tibiae at low doses, the fPth1 was positively correlated with trabecular bone volume/total volume (TbBV/TV) while hPTH increased TbBV/TV, trabecular thickness (TbTh) and trabecular number (TbN). 500fPth1 and 1000fPth1 increased TbBV/TV, TbTh, TbN, mineral apposition rate (MAR) and bone formation rate/bone surface (BFR/BS) with a concomitant decrease in osteoclast surface and number. In study 2 ovariectomized (OVX), osteopenic rats and sham operated (SHAM) rats were injected intermittently with 500 μg/kg b.w. of fPth1 (500fPth1) for 11 weeks. 500fPth1 treatment resulted in increased TbBV/TV (151%) and TbTh (96%) in the proximal tibiae due to increased bone formation as assessed by BFR/BS (490%) and MAR (131%). The effect was restoration of TbBV/TV to SHAM levels without any effect on bone resorption. 500fPth1 also increased TbBV/TV and TbTh in the vertebrae (L6) and cortical thickness in the mid-femora increasing bone strength at these sites. fPth1 was similarly effective in SHAM rats. Notwithstanding the low amino acid sequence homology with hPTH (1–34), we have clearly established the efficacy of fPth1 (1–34) as an anabolic bone agent.